Head and Neck Cancer

PV QA 2 - Poster Viewing Q&A 2

MO_31_2726 - Induction Chemotherapy Plus IMRT-Based Concurrent Chemoradiotherapy Versus Induction Chemotherapy Plus IMRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study

Monday, October 22
10:45 AM - 12:15 PM
Location: Innovation Hub, Exhibit Hall 3

Induction Chemotherapy Plus IMRT-Based Concurrent Chemoradiotherapy Versus Induction Chemotherapy Plus IMRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study
Z. Wei1, Z. Zhang2, P. Li1, and X. Peng3; 1Cancer Center, West China Hospital, Sichuan University, Chengdu, China, 2West China Hospital, Sichuan University, Chengdu, China, 3State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Purpose/Objective(s): In the era of intensity modulated radiation therapy (IMRT), the value of concurrent chemotherapy after induction chemotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma is not yet clear.

Materials/Methods: Between January 2008 and December 2014, a total of 156 locoregionally advanced NPC patients who received induction chemotherapy TPF (docetaxel, cisplatin, 5-fluorouracil) plus IMRT with or without triweekly cisplatin were included in the study population. Overall survival (OS), progression-free survival (PFS), locoregional recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were evaluated by the Kaplan-Meier method and a log-rank test. Cox proportional hazard regression analysis was applied to identify the independent prognostic factors. Treatment toxicities were clarified and compared between two groups.

Results: 77 patients received induction chemotherapy plus IMRT-based concurrent chemoradiotherapy (IC+CCRT) while 79 patients underwent induction chemotherapy plus IMRT alone (IC+RT). There were no differences between two groups in clinicopathological characteristics including age, gender, T stage, N stage. With a median follow-up of 40 months, no differences were observed between the IC+CCRT group and the IC+RT group in 3-year OS (92.3% vs. 94.9%, p=0.083), PFS (81.8% vs. 77.4%, p=0.262), LRFS (88.0% vs. 88.5%, p=0.230), and DMFS (86.8% vs. 80.3%, p=0.970). Multivariate analysis showed that treatment group (IC+CCRT vs. IC+RT) was not an independent prognostic factor for 3-year OS (HR, 2.656; 95% CI, 0.674-10.468; p=0.163), PFS (HR, 1.382; 95% CI, 0.693-2.757; p=0.359), LRFS (HR, 2.173; 95% CI, 0.757-6.234; p=0.149), DMFS (HR, 0.914; 95% CI, 0.394-2.120; p= 0.833). The addition of concurrent chemotherapy was not associated with increased rates of treatment associated toxicities.

Conclusion: The addition of concurrent chemotherapy to IMRT after induction chemotherapy TPF did not significantly improve survival in locoregionally advanced nasopharyngeal carcinoma.

Author Disclosure: Z. Wei: None. Z. Zhang: None. P. Li: None. X. Peng: None.

Xingchen Peng

Biography:
Xingchen Peng

M.D., Ph.D. Radiation Oncologist
Department of Head and Neck Cancer, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
No.37 Guo Xue Xiang, Chengdu, Sichuan, 610041, P.R China
Phone number: (+86) 028-85164059
Fax number: (+86) 028-85164060.
E-mail: pxx2014@scu.edu.cn

Research Interests
Comprehensive Treatment of Nasopharyngeal Carcinoma
Intensity-Modulated Radiotherapy of Head and Neck Cancer
Education
May., 2016 - May., 2018, Radiation Oncology, Harvard Medical School- Massachusetts General Hospital, Post doctor
Sep., 2009 - Jun., 2012, Oncology, West China School of Medicine, Sichuan University, Doctor
Sep., 2006 - Jun., 2009, Oncology, West China School of Medicine, Sichuan University, Master
Sep., 2001 - Jun., 2006, Clinical medicine, Zunyi Medical School, Bachelor
Academic Appointments
Associate Professor and Master's Supervisor, Oncology, Department of Head and Neck Cancer, Cancer Center, West China Hospital, Sichuan University
Administrative Appointments
Committee Member, Committee of Precision Radiotherapy in Head and Neck Cancer, Chinese Society of Biomedical Engineering
Committee Member, Committee of Anti-Cancer Agent, Sichuan Anti-Cancer Association
Awards
35 under 35. One of the 35 Young Oncologists Under the Age of 35 with the Greatest Potential. Chinese Society of Clinical Oncology. 2017
Grants
Two Grants Supported by National Natural Sciences Foundation of China
Two Grants Supported by Science and Technology Department of Sichuan Province
Two Grants Supported by Chinese Society of Clinical Oncology
Publications
Twenty-Six Papers (First Author or Corresponding Author) in Science Citation Index
Two Monographs

Presentation(s):

Send Email for Xingchen Peng


Assets

MO_31_2726 - Induction Chemotherapy Plus IMRT-Based Concurrent Chemoradiotherapy Versus Induction Chemotherapy Plus IMRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Induction Chemotherapy Plus IMRT-Based Concurrent Chemoradiotherapy Versus Induction Chemotherapy Plus IMRT Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study